NCT/Study#

SY-1425-202

Phase II RARA(+) ACTIVEly Diagnosed/Untreated AML study with Venetoclax/Azacitidine and SY-1425 with the primary objective to characterize the safety and tolerability of the triplet regimen.

Phase II RARA(+) ACTIVEly Diagnosed/Untreated AML study with Venetoclax/Azacitidine and SY-1425 with the primary objective to characterize the safety and tolerability of the triplet regimen.

DISEASE GROUP:
Leukemia
current phase:
Phase II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: